Aliqopa Disease Interactions

Copanlisib is primarily metabolize by the liver. Based on the population pharmacokinetic analysis, no clinically relevant difference was observed in patients with mild hepatic impairment. The pharmacokinetics of copanlisib have not been evaluated in patients with moderate to severe hepatic impairment. Close monitoring is recommended in these patients.

Hyperglycemia has occurred in patients treated with copanlisib. Before starting copanlisib patients should achieve optimal blood glucose control and dose should be reduced, or therapy temporarily discontinued depending on the severity and persistent of hyperglycemia. Diabetic patients should only be treated with this agent following adequate glucose control and should be monitored closely.

Hypertension has occurred in patients treated with copanlisib. Before starting copanlisib patients should achieve optimal blood pressure control and dose should be reduced, or therapy temporarily discontinued depending on the severity and persistence of hypertension. It is recommended to monitor blood pressure before and after the infusion with copanlisib.

Serious infections, including infections and non-infectious pneumonitis, have occurred in patients treated with copanlisib. Care should be exercised in patients at risk as in those at increased susceptibility to infection, such as neutropenic patients or those with a prior history of jiroveci pneumonia infection. It is recommended to monitor patients closely according to medical practice and for signs and symptoms of infection and to treat as medically appropriate. The dose should be reduced, or therapy temporarily discontinued depending on the severity and persistence of symptoms.

Copanlisib undergoes minimal renal elimination. Based on the population pharmacokinetic analysis, no clinically relevant difference was observed in patients with mild or moderate renal impairment. The pharmacokinetic copanlisib has not been evaluated in patients with severe renal impairment or in those patients with end stage renal disease with or without dialysis. Close monitoring is recommended in these patients.